HOME / Technology Platforms / Single Cell Technology Platform
Technology Platforms

Single Cell Technology Platform

Harbour Mice®

Bispecific Antibodies

Antibody Discovery Solution

Back to list

Harbour BioMed has set up single cell technology since early 2019. By utilizing the optofluidic technology, we established the full process of single B cell cloning, including murine CD138+ plasma cell enrichment, single B cell separation in chip, antibody binding and functional in-chip screening methods, single cell antibody sequencing, high throughput recombinant antibody production and verification, etc. Comparing with the traditional monoclonal antibody screening technology, the single B cell cloning as an advanced new technology can greatly increase the efficiency and productivity of antibody drug discovery.







Harbour BioMed has established a robust pipeline in oncology and immunology since the company was established in 2016. The current portfolio includes five clinical-stage in-licensed compounds and a rapidly emerging set of therapeutics coming from its internal discovery efforts as well as co-discovery/development collaborations with academic institutions and biopharmaceutical companies.

contact us